__________________
Senast redigerad av Pellefant775 2025-07-16 kl. 16:34.
Senast redigerad av Pellefant775 2025-07-16 kl. 16:34.
. Så det är nog du som behöver starta igång en utredning.
. Så det är nog du som behöver starta igång en utredning.
. Det är du som tillskriver mig åsikter. Det jag säger är att impact factorn inte ger en artikel automatisk legitimitet så det är meningslöst att ta upp det om och om igen. Sluta nämn det bara och länka till bra artiklar istället.
July 18 (Reuters) - Moderna (MRNA.O), opens new tab said on Friday it will not proceed with plans to build a messenger RNA manufacturing plant in Japan due to "changes in the business environment" around the world and in Japan.Visst är det "intressant" att jämföra horden av forskare som ensidigt och ovetenskapligt talade sig varma för vaccinen när nya data nu visar allvarligare hjärtproblem än man tidigare anat.
The company has been battered by declining revenue from its COVID-19 shots and less-than-expected uptake of its respiratory syncytial virus vaccine, and has been banking on revenue from newer mRNA shots to make up for weak revenue. https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-cancels-plans-build-japan-plant-poor-business-environment-2025-07-18/
US FDA Safety Labeling Change for mRNA COVID-19 VaccinesVi tar väl och fetar detta, för pajasar som er;
On June 25, 2025, the US Food and Drug Administration (FDA), in conjunction with manufacturers, added class safety warnings for myocarditis and pericarditis to COVID-19 messenger RNA (mRNA) vaccines’ prescribing information. The new warning expands knowledge regarding the age range and severity of myocarditis, noting that the estimated unadjusted incidence of myocarditis and/or pericarditis was approximately 27 cases per 1 000 000 (or 1 in 37 000) in males aged 12 to 24 years for the 2023 to 2024 formula of mRNA COVID-19 vaccines, and that “at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common.” The data do not allow disambiguating risk by manufacturer.
This action follows new data from a multi-institutional, retrospective study sponsored by the FDA.1 That study included 333 patients hospitalized with myocarditis after receiving a COVID-19 vaccine, in whom no alternative etiology was considered plausible. The median age was 16 years, and 96% presented with chest pain with a mean onset of 3.2 days after vaccination. Notably, 82% (177/216) of vaccine-associated myocarditis cases evaluated by cardiac magnetic resonance imaging had late gadolinium enhancement (LGE). LGE is associated with worse outcomes in other cardiac disease states2 and for patients with myocarditis.3
Most concerning, over a median follow-up of 159 days, 60% of individuals (98/161) with initial LGE had persistence and a minority (5% [5/98]) had worsening LGE and symptoms. A total of 4% of patients (11/272) continued to have arrhythmias at a median follow-up of 31 days and 2% required antiarrhythmic medications. These findings raise questions about the benefit-risk assessment for COVID-19 vaccination in healthy male adolescents and young adults. https://jamanetwork.com/journals/jama/fullarticle/2836670De nya och allvarligare resultat som framkommit senare tiden kan komma att leda till skadeståndsutbetalningar som blir spiken i kistan för Pfizer och Moderna. Man kan läsa om dessa risker till exempel den 30 maj i AInvest:
The rapid rise of mRNA vaccines like Pfizer-BioNTech's Comirnaty and Moderna's Spikevax has been one of the most transformative medical achievements of the 21st century. Yet, beneath the headlines of efficacy lurks a growing risk that could undermine these companies' long-term financial stability: the mounting evidence of serious adverse events of special interest (AESIs) and the potential liabilities they portend. As new clinical trial and post-authorization data reveal alarming trends in excess AESI rates, investors must confront a stark reality: the hidden costs of mRNA vaccine production could soon eclipse their perceived value.Ja vi tar väl ett till citat ur samma artikel för vaxxar-försäljarna:
The Clinical Trial Data: A Red Flag for Long-Term Liability Recent analyses of phase III trial data reveal that mRNA vaccines carry a statistically significant excess risk of serious AESIs compared to placebos. Combined data for Pfizer PFE -0.45% and Moderna vaccines show an excess of 12.5 serious AESIs per 10,000 doses administered, with a risk ratio of 1.43 (95% CI: 1.07–1.92). While this may seem small, the implications are profound (...) Crucially, these risks are not theoretical. Post-marketing surveillance of over 772 million doses administered globally has confirmed heightened rates of myocarditis (heart inflammation) and pericarditis (heart lining inflammation), particularly in males aged 12–40. For example, the observed-to-expected (OE) ratio for myocarditis in this group was 8.57 after the second dose, far exceeding background rates. https://www.ainvest.com/news/risk-alert-mrna-vaccine-manufacturers-face-growing-liability-threats-safety-data-2505/
July 18 (Reuters) - Moderna (MRNA.O), opens new tab said on Friday it will not proceed with plans to build a messenger RNA manufacturing plant in Japan due to "changes in the business environment" around the world and in Japan.
The company has been battered by declining revenue from its COVID-19 shots and less-than-expected uptake of its respiratory syncytial virus vaccine, and has been banking on revenue from newer mRNA shots to make up for weak revenue. https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-cancels-plans-build-japan-plant-poor-business-environment-2025-07-18/
US FDA Safety Labeling Change for mRNA COVID-19 VaccinesVi tar väl och fetar detta, för pajasar som er;
On June 25, 2025, the US Food and Drug Administration (FDA), in conjunction with manufacturers, added class safety warnings for myocarditis and pericarditis to COVID-19 messenger RNA (mRNA) vaccines’ prescribing information. The new warning expands knowledge regarding the age range and severity of myocarditis, noting that the estimated unadjusted incidence of myocarditis and/or pericarditis was approximately 27 cases per 1 000 000 (or 1 in 37 000) in males aged 12 to 24 years for the 2023 to 2024 formula of mRNA COVID-19 vaccines, and that “at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common.” The data do not allow disambiguating risk by manufacturer.
This action follows new data from a multi-institutional, retrospective study sponsored by the FDA.1 That study included 333 patients hospitalized with myocarditis after receiving a COVID-19 vaccine, in whom no alternative etiology was considered plausible. The median age was 16 years, and 96% presented with chest pain with a mean onset of 3.2 days after vaccination. Notably, 82% (177/216) of vaccine-associated myocarditis cases evaluated by cardiac magnetic resonance imaging had late gadolinium enhancement (LGE). LGE is associated with worse outcomes in other cardiac disease states2 and for patients with myocarditis.3
Most concerning, over a median follow-up of 159 days, 60% of individuals (98/161) with initial LGE had persistence and a minority (5% [5/98]) had worsening LGE and symptoms. A total of 4% of patients (11/272) continued to have arrhythmias at a median follow-up of 31 days and 2% required antiarrhythmic medications. These findings raise questions about the benefit-risk assessment for COVID-19 vaccination in healthy male adolescents and young adults. https://jamanetwork.com/journals/jama/fullarticle/2836670
The rapid rise of mRNA vaccines like Pfizer-BioNTech's Comirnaty and Moderna's Spikevax has been one of the most transformative medical achievements of the 21st century. Yet, beneath the headlines of efficacy lurks a growing risk that could undermine these companies' long-term financial stability: the mounting evidence of serious adverse events of special interest (AESIs) and the potential liabilities they portend. As new clinical trial and post-authorization data reveal alarming trends in excess AESI rates, investors must confront a stark reality: the hidden costs of mRNA vaccine production could soon eclipse their perceived value.Ja vi tar väl ett till citat ur samma artikel för vaxxar-försäljarna:
The Clinical Trial Data: A Red Flag for Long-Term Liability Recent analyses of phase III trial data reveal that mRNA vaccines carry a statistically significant excess risk of serious AESIs compared to placebos. Combined data for Pfizer PFE -0.45% and Moderna vaccines show an excess of 12.5 serious AESIs per 10,000 doses administered, with a risk ratio of 1.43 (95% CI: 1.07–1.92). While this may seem small, the implications are profound (...) Crucially, these risks are not theoretical. Post-marketing surveillance of over 772 million doses administered globally has confirmed heightened rates of myocarditis (heart inflammation) and pericarditis (heart lining inflammation), particularly in males aged 12–40. For example, the observed-to-expected (OE) ratio for myocarditis in this group was 8.57 after the second dose, far exceeding background rates. https://www.ainvest.com/news/risk-alert-mrna-vaccine-manufacturers-face-growing-liability-threats-safety-data-2505/

Du måste vara medlem för att kunna kommentera